Beqalzi Kit
NDC Package 72579-015-04
Package Information
Beqalzi (sonrotoclax) kits is bEQALZI is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.This indication is approved under accelerated approval based on response rate and durability of response. This formulation utilizes a kit delivery system. Marketed by Beone Medicines Usa, Inc., this product is identified by NDC 72579-015 and is authorized under FDA application NDA220711.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72579 - Beone Medicines Usa, Inc.
- 72579-015 - Beqalzi
- 72579-015-04 - 1 KIT in 1 KIT * 11 TABLET, FILM COATED in 1 BLISTER PACK (72579-017-04) * 11 TABLET, FILM COATED in 1 BLISTER PACK (72579-025-04) * 11 TABLET, FILM COATED in 1 BLISTER PACK (72579-022-04) * 11 TABLET, FILM COATED in 1 BLISTER PACK (72579-020-04)
- 72579-015 - Beqalzi
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72579-015-04 identifies a specific commercial package of 1 kit in 1 kit * 11 tablet, film coated in 1 blister pack (72579-017-04) * 11 tablet, film coated in 1 blister pack (72579-025-04) * 11 tablet, film coated in 1 blister pack (72579-022-04) * 11 tablet, film coated in 1 blister pack (72579-020-04) of Beqalzi, a human prescription drug labeled by Beone Medicines Usa, Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Beone Medicines Usa, Inc. on August 31, 2026. The current certification is valid through December 31, 2027.
How is this Beone Medicines Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72579001504. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.